- Home
- NMAI vs LXEO Comparison
NMAI vs LXEO Comparison
Compare NMAI & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NMAI | LXEO |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.5M | 418.9M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | NMAI | LXEO |
|---|---|---|
| Price | $13.67 | $6.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 102.2K | ★ 795.1K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.31 | $2.08 |
| 52 Week High | $13.96 | $10.99 |
Technical Indicators
Market Signals| Indicator | NMAI | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 68.72 | 49.44 |
| Support Level | $13.43 | $4.95 |
| Resistance Level | $13.90 | $7.77 |
| Average True Range (ATR) | 0.25 | 0.45 |
| MACD | 0.17 | 0.11 |
| Stochastic Oscillator | 97.70 | 70.94 |
Price Performance
Historical ComparisonAbout NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.